Tetanus

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3299A33A34A35
Who is this for?
Show terms as
3Active trials16Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Tetanus, also known as lockjaw, is an acute and potentially life-threatening infectious disease caused by the neurotoxin tetanospasmin produced by the anaerobic bacterium Clostridium tetani. It is not a genetic disorder but rather an acquired condition that occurs when bacterial spores enter the body through wounds, cuts, or other breaks in the skin. The toxin affects the nervous system by blocking inhibitory neurotransmitters in the central nervous system, leading to unopposed muscle contraction and spasm. Tetanus primarily affects the neuromuscular system and can involve the entire body. The disease is characterized by painful muscle stiffness and spasms, typically beginning with the jaw muscles (trismus or lockjaw) and neck, then progressing to involve the trunk and extremities. Generalized tetanus, the most common form, can cause opisthotonus (severe arching of the back), difficulty swallowing, breathing difficulties, autonomic dysfunction (fluctuations in blood pressure and heart rate), and potentially fatal respiratory failure. Neonatal tetanus (ICD-10: A33) occurs in newborns, usually through infection of the umbilical stump, and is a major cause of neonatal mortality in developing countries. Obstetrical tetanus (ICD-10: A34) occurs during or after pregnancy. Tetanus is entirely preventable through vaccination with tetanus toxoid-containing vaccines. Treatment includes wound care, administration of human tetanus immunoglobulin (TIG) to neutralize unbound toxin, antibiotics (typically metronidazole), muscle relaxants such as benzodiazepines, and supportive care in an intensive care setting. Mechanical ventilation may be required in severe cases. Despite advances in critical care, the case fatality rate remains significant, particularly in neonatal tetanus and in regions with limited access to healthcare. The disease does not confer natural immunity, so vaccination after recovery is essential.

Clinical phenotype terms— hover any for plain English:

TrismusHP:0000211OpisthotonusHP:0002179Risus sardonicusHP:0040212Humoral immunodeficiencyHP:0005363Intermittent painful muscle spasmsHP:0011964Stiff neckHP:0025258Spasticity of pharyngeal musclesHP:0002501
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Feb 2026TETANUS Antibody Detection in Saliva Study

University of Birmingham — NA

TrialNOT YET RECRUITING
Jan 2026A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Zhuhai Trinomab Pharmaceutical Co., Ltd.

TrialNOT YET RECRUITING
Aug 2025Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

Lanzhou Institute of Biological Products Co., Ltd — PHASE1

TrialENROLLING BY INVITATION
Jul 2025A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Zhuhai Trinomab Pharmaceutical Co., Ltd.

TrialRECRUITING
Apr 2025Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

Sinovac Life Sciences Co., Ltd. — PHASE1, PHASE2

TrialNOT YET RECRUITING
Sep 2024A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Genrix (Shanghai) Biopharmaceutical Co., Ltd. — PHASE3

TrialRECRUITING
Apr 2024Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Changchun BCHT Biotechnology Co. — EARLY_PHASE1

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Tetanus.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
Phase 3
Actively Recruiting
PI: Chuanlin Wang, MD (Peking University People's Hospital) · Sites: Hefei, Anhui; Beijing, Beijing Municipality +18 more · Age: 1899 yrs
Phase 11 trial
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
Phase 1
Enrolling by Invitation
PI: Jianchang He (Yunnan Provincial Hospital of Traditional Chinese ) · Sites: Lanzhou, Gansu · Age: 1860 yrs
Other1 trial
A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Actively Recruiting
· Sites: Shantou, Guangdong; Xiangyun, Yunnan +2 more

Specialists

16 foundView all specialists →
RM
Robert Laumbach, MD
PISCATAWAY, NJ
Specialist
PI on 1 active trial
BP
Bertrand Debaene, MD phD
Specialist
PI on 1 active trial
GM
General Manager
Specialist
PI on 14 active trials6 Tetanus publications
WW
Willem J. Wiersinga
Specialist
PI on 1 active trial
JH
Jie Hou
SUNNYVALE, CA
Specialist
PI on 2 active trials
ML
Minh Yen Lam
Specialist
PI on 1 active trial
JH
Jianchang He
Specialist
PI on 1 active trial
JS
JongHwan Shin
Specialist
PI on 1 active trial
KA
Kumar Alagappan
HOUSTON, TX
Specialist
PI on 1 active trial
CP
Christopher Parry
Specialist
PI on 1 active trial
CW
Chuanlin Wang
Specialist
PI on 2 active trials
SL
Shiguang Lei
Specialist
PI on 2 active trials
ZX
Zhiqing Xie
Specialist
PI on 1 active trial
AG
Aitana Juan Giner
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Tetanus.

Search all travel grants →NORD Financial Assistance ↗

Community

Open TetanusForum →

No community posts yet. Be the first to share your experience with Tetanus.

Start the conversation →

Latest news about Tetanus

Disease timeline:

New recruiting trial: A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

A new clinical trial is recruiting patients for Tetanus

New recruiting trial: A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

A new clinical trial is recruiting patients for Tetanus

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Tetanus

What is Tetanus?

Tetanus, also known as lockjaw, is an acute and potentially life-threatening infectious disease caused by the neurotoxin tetanospasmin produced by the anaerobic bacterium Clostridium tetani. It is not a genetic disorder but rather an acquired condition that occurs when bacterial spores enter the body through wounds, cuts, or other breaks in the skin. The toxin affects the nervous system by blocking inhibitory neurotransmitters in the central nervous system, leading to unopposed muscle contraction and spasm. Tetanus primarily affects the neuromuscular system and can involve the entire body. Th

Are there clinical trials for Tetanus?

Yes — 3 recruiting clinical trials are currently listed for Tetanus on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Tetanus?

16 specialists and care centers treating Tetanus are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.